Dolutegravir

  • Part D specialty tier in 60% of formularies (2026Q3)
  • Tivicay

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Dolutegravir: storage and handling

Freezing
Not addressed
Room temperature
at or below 25°C (77°F)
Label statement
Store TIVICAY 10-mg, 25-mg, and 50-mg tablets at room temperature between 68°F to 77°F (20°C to 25°C).
Room temperature
at or below 30°C (86°F)
Label statement
Store TIVICAY PD 5-mg tablets for oral suspension at room temperature below 86°F (30°C) in the original bottle.
Back into the refrigerator
Not addressed
Light
Not addressed
Shaking
Not addressed

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

Within the label's stated room-temperature allowance (at up to 25°C (77°F)). Follow the label's instructions for what to do next.

Entered: 1 day at up to 77°F (25°C).

Store TIVICAY 10-mg, 25-mg, and 50-mg tablets at room temperature between 68°F to 77°F (20°C to 25°C).

If anything else happened to the product, or you are unsure, Contact the manufacturer at 1-877-844-8872 (the number printed on the label) about this product.

Where the label prints this number
TVC:14PIL For more information, go to www.TIVICAY.com or call 1-877-844-8872.
All storage statements on the label (4)
  • Store TIVICAY 10-mg, 25-mg, and 50-mg tablets at room temperature between 68°F to 77°F (20°C to 25°C).
  • Store TIVICAY 10-mg tablets in the original bottle.
  • Store TIVICAY PD 5-mg tablets for oral suspension at room temperature below 86°F (30°C) in the original bottle.
  • Instruct patients and caregivers to store the TIVICAY 10-mg tablets and TIVICAY PD 5-mg tablets for oral suspension in the original package, keep the bottle tightly closed, and protect from moisture.

FDA label version 2, effective May 22, 2026. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

100%of plans list it
0%of those: prior authorization
0%step therapy
57%quantity limit
88%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.